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Abstract
Background: Study of drug-target interaction networks is an important topic for drug development. It is both time-
consuming and costly to determine compound-protein interactions or potential drug-target interactions by experiments
alone. As a complement, the in silico prediction methods can provide us with very useful information in a timely manner.
Methods/Principal Findings: To realize this, drug compounds are encoded with functional groups and proteins encoded by
biological features including biochemical and physicochemical properties. The optimal feature selection procedures are
adopted by means of the mRMR (Maximum Relevance Minimum Redundancy) method. Instead of classifying the proteins as
a whole family, target proteins are divided into four groups: enzymes, ion channels, G-protein- coupled receptors and
nuclear receptors. Thus, four independent predictors are established using the Nearest Neighbor algorithm as their
operation engine, with each to predict the interactions between drugs and one of the four protein groups. As a result, the
overall success rates by the jackknife cross-validation tests achieved with the four predictors are 85.48%, 80.78%, 78.49%,
and 85.66%, respectively.
Conclusion/Significance: Our results indicate that the network prediction system thus established is quite promising and
encouraging.
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Introduction
Identification of drug-target interaction networks is an essential
step in the drug discovery pipeline [1]. The emergence of
molecular medicine and the completion of the human genome
project provide more opportunity to discover unknown target
proteins of drugs. Many efforts have been made to discover new
drugs in the past few years. However, the number of new drug
approvals remains quite low (around only 30 per year). This is
partially because many compounds or drug candidates have to be
withdrawn owing to unacceptable toxicity. Such failures have
wasted a lot of money. It would be beneficial to develop
computational methods for predicting the sensitivity and toxicity
before a drug candidate was synthesized [2,3,4]. However, a
number of problems need to be overcome in order to find out the
exact effects of a drug. Firstly, drugs could have numerous effects
including positive and negative effects, and it is hard to find out
and elucidate the possible effects; secondly, different people would
have completely different responses to a drug even though the
same gene products are only slightly different [5,6,7,8]; thirdly, it is
very hard to trace the drug effects since the biological interaction
pathways are extremely complicated in human beings. Therefore,
it would be very helpful for drug development if the interactions
between drugs and target proteins could be predicted more
accurately and the underlying mechanisms could be better
understood.
Several computational approaches have been developed for
analyzing and predicting drug-protein interactions. The most
commonly used are docking simulations [9,10,11,12], literature
text mining [13], and combining chemical structure, genomic
sequence, and 3D structure information [14], among others (see,
e.g., [15,16,17]).
Machine learning and data mining methods have been widely
used in the computational biology and bioinformatics area. Many
researchers have made lots of efforts to develop useful algorithms
and softwares to investigate various drug-related biological
problems, such as HIV protease cleavage site prediction [18,19],
identification of GPCR (G protein-coupled receptors) type [20,21],
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prediction [23,24,25], analysis of specificity of GalNAc-transferase
protein [26], identification of protease type [27,28], membrane
protein type prediction [29,30,31,32], and a series of relevant web-
server predictors as summarized in a recent review [33].
Here we propose a predictor for drug-target interactions based
on the Nearest Neighbor algorithm [34]. Since biochemical and
physicochemical features [35] are important for characterizing
proteins, in this study they are used to represent proteins as done
by many previous investigators (see, e.g., [36,37,38]. To improve
the predictor’s performance, minimum Redundancy Maximum
Relevance (mRMR) algorithm [39] is used to rank the features.
Meanwhile, the Incremental Feature Selection and Forward
Feature Selection are applied for feature selection. The protein
targets for drugs are divided into enzymes, ion channels
[40,41,42,43], GPCRs [44,45], and nuclear receptors [14] in this
study. Finally, four predictors for predicting the interactions of
drugs with each of the four protein families are developed in hopes
that they can help provide useful information for drug design.
Materials and Methods
Benchmark Datasets
In addition to the dataset used by Yamanishi et al. [14],
information about drug compounds and genes can be obtained
from KEGG [46,47] by the FTP operations: ftp://ftp.genome.jp/
pub/kegg/ligand/drug/drug for the drugs, and ftp://ftp.genome.
jp/pub/kegg/genes/fasta/gene.pep for the genes. After excluding
the drug-target pairs that lack experimental information, we finally
obtained a total of 4,797 drug-target pairs, of which 2,719 for
enzymes, 1,372 for ion channels, 630 for GPCRs, and 82 for
nuclear receptors. All these datasets were used as the positive
datasets in the current study.
The corresponding negative datasets were derived from the
above positive datasets via the following steps: (1) separate the
pairs in the above positive dataset into single drugs and proteins;
(2) re-couple these singles into pairs in a way that none of them
occurs in the corresponding positive dataset; (3) randomly picked
the negative pairs thus formed until they reached the number two
times as many as the positive pairs.
The drug-target benchmark datasets thus obtained for enzymes,
ion-channels, GPCRs, and nuclear receptors are given in Online
Supporting Information S1, S2, S3, and S4, respectively.
Feature Vector Construction
Representing drugs with chemical functional groups
composition. The number of drugs is extremely large.
However, most of them are small organic molecules and are
composed of some fixed small structures, called functional groups.
Since functional groups usually represent the characteristics of a
compound as well as its reaction mechanism with other molecules,
features derived from its functional groups could be very effective in
characterizingadrug.Moreover,thenumberofcommonfunctional
groups is quite small, and hence it is possible to use the functional
group composition to uniquely represent a drug [48]. A number of
functional groups are available in nature, and we selected the
following 28 common groups for the current study: (1) alcohol, (2)
aldehyde, (3) amide, (4) amine, (5) hydroxamic acid, (6) phosphorus,
(7) carboxylate, (8) methyl, (9) ester, (10) ether, (11) imine, (12)
ketone, (13) nitro, (14) halogen, (15) thiol, (16) sulfonic acid, (17)
sulfone, (18) sulfonamide, (19) sulfoxide, (20) sulfide, (21) a_5c_ring,
(22) ar_6c_ring, (23) non_ar_5c_ring, (24) non_ar_6c_ring,
(25) hetero ar_6_ring, (26) hetero non_ar_5_ring, (27) hetero
non_ar_6_ring,and(28)heteroar_5_ring.Thus,followingthesame
treatment as in [23], a drug compound can now be formulated as a
28-D (dimensional) vector given below:
D~ g1 g2     gi     g28 ½ 
T ð1Þ
where gi (i~1, 2,    , 28) is the occurrence frequency of the i-th
functional group in the drug D,a n dT the matrix transpose
operator.
Representing target proteins with pseudo amino acid
composition by incorporating biochemical and physi-
cochemical features. Now the problem is how to effectively
represent a target protein. Two kinds of representations are
generally used in this regard: the sequential representation and the
non-sequential representation. The most typical sequential
representation for a protein sample is its entire amino acid
sequence, which can contain the most complete information of a
protein. To deal with this model, the sequence-similarity-search-
based tools, such as BLAST [49], are usually used to find the
desired results. Unfortunately, this kind of approach failed to work
when the query protein did not have significant homology to the
proteins in the training dataset. Thus, various non-sequential
representations or discrete models were proposed. The simplest
discrete model was based on the amino acid composition (AAC)
(see, e.g., [50]). However, if using the AAC model to represent a
protein, all its sequence-order information will be lost. To avoid
completely losing the sequence-order information, the pseudo
amino acid composition (Pse-AAC) was proposed [36] to represent
the sample of a protein. The PseAAC can be used to represent a
protein sequence with a discrete model yet without completely
losing its sequence-order information. For further information
about PseAAC, see the web-page by clicking the link http://en.
wikipedia.org/wiki/Pseudo_amino_acid_composition. Ever since the
concept of PseAAC was introduced, it has been widely used to study
various problems in proteins and protein-related systems (see, e.g.,
[37,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66]). Meanwhile,
many different forms of discrete models were also proposed (see,
e.g., [20,30,32,51,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82]).
However, regardless of how much different these models are, they
just belong to different forms of PseAAC, as elucidated in a recent
comprehensive review [83]. Here, we are to propose a different
PseAAC to represent drug-targeted proteins in terms of their
biochemical and physicochemical features [84]. Six different types
of features were considered: (1) hydrophobicity, (2) polarizability, (3)
polarity, (4) secondary structure, (5) normalized van der Waals
volume, and (6) solvent accessibility.
Each amino acid residue in a protein sequence can be
represented by a set of different states according to its features.
For instance, its hydrophobicity feature can be marked by one of
the following three states: ‘‘polar’’, ‘‘neutral’’, or ‘‘hydrophobic’’
[85]; its solvent accessibility feature by one of the two: ‘‘buried’’ or
‘‘exposed to solvent’’, as predicted by PredAcc [35]; its secondary
structure feature by one of the three: ‘‘helix’’, ‘‘sheet’’, or ‘‘coil’’, as
predicted by the method in [86]; and so forth.
Thus, a protein sequence can be translated to a series of codes
according to the biochemical and physicochemical properties of its
constituent amino acid residues. For example, if using ‘‘P’’, ‘‘N’’ and
‘‘H’’ to represent the three states of hydrophobicity: ‘‘polar’’, ‘‘neu-
tral’’, and ‘‘hydrophobic’’, the protein sequence ‘‘DMAEIMSDKP-
QAGML’’ can be translated to ‘‘PHNPHHNPPNPNNHH’’ accord-
ing to the codes of the hydrophobic property feature. The encoded
sequences thus obtained would have different length for proteins of
different sizes, which will make the prediction engine difficult to handle.
To make the feature-encoded sequence to be a vector with a
fixed number of dimensions, three properties of a sequence was
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represents the global composition of each letter in the sequence; T,
the frequency of a code letter changing from one to another; D,
the distribution pattern of the code letters along the sequence,
measuring the percentage of the sequence length within which the
first, 25%, 50%, 75%, and 100% of the amino acids of each code
letter is located. Take the above hydrophobic property sequence as
an example: its C feature is 5/15=33.3% for all of P, H, and N,
while the T feature is 2/10=20%, 3/10=30% and 5/10=50%
for the changes between H and P, N and H, N and P, respectively.
The measurement of feature D is a little more complicated. For
the letter H, the first, 25%, 50%, 75% and 100% of Hs in the
sequence is located at the position of 2, 5, 6, 14, and 15. Thus
its D feature is (2/15=13.3%, 5/15=33.3%, 6/15=40%, 14/
15=93.3%, 15/15=100%). In the same way, the distributions of
letters P and N are (6.7%, 26.7%, 53.3%, 60%, 73.3%) and (20%,
46.7%, 66.7%, 80%, 86.7%), respectively. Accordingly, the three
features of the code letter sequence are: C=(33.3%, 33.3%,
33.3%), T=(20%, 30%, 50%), and D=(13.3%, 33.3%, 40%,
93.3%, 100%, 6.7%, 26.7%, 53.3%, 60%, 73.3%, 20%, 46.7%,
66.7%, 80%, 86.7%), with a total of 21 components. Likewise, for
the sequences encoded by the other four biochemical properties,
each is also corresponding to 21 components. But for the sequence
encodedbythe solventaccessibilitywithonlytwostates(‘‘buried’’or
‘‘exposed to solvent’’), the encoded sequence is corresponding to
only 14 components. Finally, by adding the 20 components of AAC
[87] into the vector concerned, the total number of components
thus obtained for a given protein is 5|21z20z14~139; i.e., the
protein can be formulated as a 139-D vector given by
P~ p2 p2     pi     p239 ½ 
T ð2Þ
where pi (i~1, 2,    ,1 3 9 )is the i-th component of the protein P.
Of the 139 components, 119 are derived according to the codes of
the above six biochemical and physicochemical features, and 20 are
the AAC components of P.
Nearest Neighbor Algorithm
With all samples represented by a feature vector, now it is
possible for us to construct our predictor using the machine
learning approach. The NN (Nearest Neighbor) algorithm is quite
popular in pattern recognition community owing to its good
performance and simple-to-use feature. According to the NN
rule [88], the query sample should be assigned to the subset
represented by its nearest neighbor. In this study, if the drug-target
pair with the shortest distance is a positive sample, meaning that
they can interact with each other, the sample for test is seen as a
positive drug-target pair. Otherwise, the test sample is seen as a
negative one.
There are many different definitions to measure the ‘‘nearness’’
for the NN algorithm, such as Euclidean distance, Hamming
distance [89], and Mahalanobis distance [50,90,91]. In the current
study, the following equation was adopted to measure the nearness
between samples Vx and Vy
D(Vx,Vy)~1{
Vx:Vy
Vx kk Vy
        ð3Þ
where Vx:Vy is the dot product of the two vectors, and Vx kk and
Vy
        their modulus, respectively. When Vx:Vy we have
D(Vx,Vy)~0, indicating the ‘‘distance’’ between these two sample
vectors is zero and hence they have perfect or 100% similarity.
Jackknife Cross-Validation Test
After constructing the drug-target interaction predictor, we have to
evaluate its performance. In statistical prediction, the following three
cross-validation methods are often used to examine a predictor for its
effectiveness in practical application: independent dataset test,
subsampling (K-fold cross-validation) test, and jackknife test [92].
However, as elucidated by [24] and demonstrated by Eq.50 in [93],
among the three cross-validation methods, the jackknife test is
deemed the most objective that can always yield a unique result for a
given benchmark dataset, and hence has been increasingly used and
widely recognized byinvestigatorsto examine the accuracyof various
predictors (see, e.g. [51,53,54,55,56,57,59,62,63,64,94,95,96]).’’ Ac-
cordingly, in this study the jackknife cross-validation was adopted to
calculate the success prediction rates as well.
Maximum Relevance Minimum Redundancy (mRMR)
Although we’ve constructed the drug-target predictor based on
the original feature set described above, it is possible to improve its
performance with a better feature set. Apparently, not every feature
in the feature set is equally relevant to the drug-target interaction.
What’s more, features may not be independent with each other. The
‘‘bad’’ will have negative impact on the accuracy and efficiency of
the predictor, so it is possible to do the feature selection process to
construct a more compact and effective feature set. The first step is
using Maximum Relevance Minimum Redundancy (mRMR) [36]
to do feature evaluation. Maximum Relevance Minimum Redun-
dancy (mRMR) [39] was firstly developed for analysis of microarray
data.Itrankseachfeatureaccordingtoitsrelevanceto thetargetand
redundancy to other features. The better a feature is deemed to be,
the higher the rank it will be assigned to. Mutual information (MI),
denoted by I to indicate the dependence of two features used to
quantify the relevance and redundancy. MI is defined as following:
Ix ,y ðÞ ~
ðð
px ,y ðÞ log
px ,y ðÞ
px ðÞ py ðÞ
dxdy ð4Þ
Based on MI, we can quantify relevance (D) and redundancy (R)
as:
D~If candidate,c ðÞ ð 5Þ
R~
1
m
X
fi[Vs
If candidate,fi ðÞ ð 6Þ
where fcandidate is the feature to be calculated, and c is the target
variable. By combining the above two equations to maximize
relevance and minimize redundancy, the following mRMR function
is constructed:
max
fj [ Vt
I(fj,c){
1
m
X
fi [ Vs
I(fj,fi)
2
4
3
5(j~1, 2, :::, n) ð7Þ
where Vs and Vt are the already-selected feature set and to-be-
selected feature set, respectively, and mand nare the sizes of these two
feature sets, respectively. The earlier a feature is selected, the better it
would be though of. Finally, we can get an ordered feature list with a
rank for every feature to indicate its importance in the feature set. In
our study, the mRMR program is obtained from: http://research.
janelia.org/peng/proj/mRMR/index.htm.
Drug-Target Interactions
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probabilistic densities of the two vectors were used. A parameter t
is introduced here to deal with these variables. Suppose mean to
be the average value of one feature in all samples, and std to be the
standard deviation, the feature of each sample would be classified
into one of the three groups according to the boundaries:
mean+(t:std). In our study, t was assigned to be 1.
Incremental Feature Selection
As mentioned above, the importance of each feature is rated
according to its rank in the mRMR analysis. The next step is to
determine which features should be selected as the optimal feature
set for our drug-target predictor. Here the IFS (Incremental
Feature Selection) procedure is used to solve the problem. Each
feature in the mRMR feature list was added one by one, and N
different feature sets are obtained if the total feature number is N,
while the i-th feature set is:
Si~ff1, f2, :::, fig (1ƒiƒN) ð8Þ
Based on each of the N feature sets, an NN algorithm predictor
was constructed and tested with the jackknife cross-validation test.
With all the N overall accurate rates calculated, we could draw an
IFS curve with the index i to be the x-axis and the corresponding
overall accurate rate to be the y-axis. Thus, Sopt~ff1, f2, :::, fng is
regarded as the optimal feature set if the curve reach its peak
where the value of its x-axis is nƒN.
Because four independent predictors are needed for the four
different classes of drug-target pairs, the IFS analysis procedure
will be processed four times with each for a specific predictor.
Forward Feature Selection
To refine feature selection, the FFS (Forward Feature Selection)
procedure based on the result of IFS was used. FFS is a feature
selection method based on IFS results which tries every feature in
the candidate feature set and adds the feature that achieves the
highest prediction accuracy into the already-selected feature set in
each goes. Suppose the IFS curve reaches its peak with apex as its
x-axis, the initial FFS-selected feature set was constructed as:
SFFS~ff’1, f’1, :::, f’kg (1ƒkƒapex) ð9Þ
More features in FFS-to-be-selected feature set would be added
into the FFS-selected feature set one by one. The FFS-to-be-
selected feature set with M features covers the features with
mRMR ranks between k+1 and k+1+M, where M is a user-defined
positive integer smaller than N{k with N to be the size of the
original feature set. In each round of FFS, each feature in FFS-to-
be-selected feature set would be taken out and added to the FFS-
selected feature set. Each predictor based on each new FFS-
selected feature set would be tested, and the feature set obtained
the highest overall accurate rate would be used as the new FFS-
selected feature set. This process would be run for M times, until
the FFS-to-be-selected feature set becomes a null set. An FFS
curve similar to the IFS curve could be drawn with x-axis as the
index and y-axis as the overall accurate rate.
In this study, FFS was run for each of the four benchmark
datasets based on the corresponding IFS result. M for all these
processes was set to 50, while k for each FFS was set to be the
index of the point with the first maximum value (i.e. the maximum
point with the smallest index) in the corresponding IFS curve.
Results and Discussion
Results of mRMR
To improve performance of the predictor of drug-target
interaction, feature selection process was carried out. The first
step of feature selection is feature evaluation. In this study, mRMR
was used to evaluate every feature in original feature set. Listed in
Online Supporting Information S5 are two kinds of outputs: the
first one is the MaxRel list which shows ranks of features for their
relevance to the target; the second is mRMR list showing the
mRMR ranks according to the feature order satisfying Eq. 3. In
this study, only the mRMR list was used as the results of feature
evaluation. Since there are four groups of samples, mRMR was
run four times with each for one of them.
Results of IFS and FFS
With the four mRMR lists, IFS was processed for each of the
four sample groups, generating four IFS curves. Based on these
results, we set k in FFS to be 16, 15, 14 and 19 for the data of
enzymes, ion channels, GPCRs and nuclear receptors, respective-
ly. Each of these figures is the index of the point of the first
maximum value in the corresponding IFS curve. Shown in Fig. 1
are the four IFS curves with their corresponding FFS curves. The
peaks of the four FFS curves finally reach the overall success rates
of 85.48% with 32 features, 80.78% with 37 features, 78.49% with
30 features, and 85.66% with 32 features for enzyme group, ion
channel group, GPCR group and nuclear receptor groups,
respectively.
Features selected by mRMR+FFS for the four different groups
are quite different from each other, showing the intrinsic
differences between them. Although there are more features for
target than those for drug in the original feature set, more drug
features were selected, showing the important role of drugs. Many
of the selected target features are for protein secondary structure,
especially for enzyme group (half of selected target features are for
this). All types of features are selected in at least one group,
showing that all biochemical and physicochemical features have
their irreplaceable positions in drug-target interaction process.
For the details of the optimal feature-set outputs by FFS
for the four benchmark datasets, see the Online Supporting
Information S6.
Discussions
For the specificity and promiscuity, we divided the drug-protein
interactions into four groups according to the targets of drugs:
enzymes, ion channels, GPCRs, and nuclear receptors. We used
all the known drugs and target proteins in the gold standard data
as training data to predict the potential interactions between all
human proteins annotated as members of the four classes in
KEGG genes and all compounds in KEGG ligands.
Enzyme recognition is the primary event involved in the
interaction of proteins with other proteins and with small
molecules such as metabolites and therapeutics. Predicting drug-
enzyme interactions has direct application for completing genome
annotations, finding enzymes for synthetic chemistry, and
predicting drug specificity, promiscuity and pharmacology. It is
suggested that the secondary structure information plays the major
role in determining the drug-enzyme interactions activity. For
example, cytochrome P450 (CYP) induction-mediated interaction
is one of the major concerns in clinical practice and for the
pharmaceutical industry [97]. Induction of CYP1A enzymes with
a specific structure-stable state may activate some xenobiotics to
their reactive metabolites, leading to toxicity [98,99]. Amino acid
composition and hydrophobicity also contribute considerably to
Drug-Target Interactions
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the angiotensin I-converting enzyme (ACE) have an influence on
the antihypertensive response, particularly when using ACE
inhibitors (ACEI) [100], mirroring that the amino acid composi-
tion did contribute to the interactions. Hydrophobicity plays a role
in determining the coefficients of drug-enzyme interaction energy
with the application to drug screening as well as in silico target
protein screening [101,102].
The G-protein coupled receptor (GPCR) superfamily, which is
comprised of estimated 600–1,000 members, is another largest
known class of molecular targets with varieties of physiological
activities and proven therapeutic value [103]. They are integral
membrane proteins sharing a common global topology that
consists of seven transmembrane alpha helices, intracellular C-
terminal, an extracellular N-terminal, three intracellular loops and
three extracellular loops [33,44]. It is suggested that secondary
structure and polarity would play a major role in determining the
drug-GPCRs interactions activity. Small secondary structures such
as helices and loops are identified as entities potentially involved in
stabilizing interactions with ligands [33]. These motifs were
situated mainly in the apical region of transmembrane segments
and included a few extracellular residues [104]. Crystal structures
of engineered human beta 2-adrenergic receptors (ARs) in
complex with an inverse agonist ligand, carazolol, provide three-
dimensional snapshots of an important G protein-coupled receptor
(GPCR) with a beta-sheet structure and forms part of the
chromophore-binding site [105]. GLIDA provides interaction
data between GPCRs and their ligands, along with chemical
information on the ligands, as well as biological information
regarding GPCRs [106]. Some of the features reflect physical
interactions that are responsible for the structural stability of the
transmembrane, the formation of extensive networks of inter-
helical H-bonds and sulfur-aromatic clusters that are spatially
organized as ‘‘polarity’’, the close packing of side-chains through-
out the transmembrane domain. When more experimental 3D
structures become available for GPCRs in the future, this will help
Figure 1. The IFS and FFS curves of the 4 groups. The detailed IFS curve with their corresponding FFS curve for (a) enzyme group, (b) ion
channel group, (c) GPCR group, and (d) nuclear receptor group.
doi:10.1371/journal.pone.0009603.g001
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suitable for docking studies. Joint use of ligand-based chemoge-
nomic and docking would certainly improve the prediction.
Ion channels are a large superfamily of membrane proteins that
pass ions across membranes and are critical to diverse physiological
functions in both excitable and nonexcitable cells and underlie
many diseases. As a result, they are an important target class which
is proven to be highly ‘‘druggable’’. According to our analysis,
secondary structure and polarity play the major role in determining
the drug-ion channels interactions activity. Secondary structure
controls the membrane potential and interrogates ion channels in
different conformational states. The drug-ion channels interaction
needs gated state where they can switch conformation between a
closed and an open state [42,43]. Simulations on model nanopores
reveal that a narrow hydrophobic region can form a functionally
closed gate in the channel and can be opened by either a small
increase in pore radius or an increase in polarity [107,108].
Nowadays, intense research is being conducted to develop new
drugs acting selectively on ion channel subtypes and aimed at the
understanding of the intimate drug–channel interaction [109].
Nuclear receptors (NR) are ligand-activated transcription factors
that regulate the activation of a variety of important target genes,
which are the most important drug targets in terms of potential
therapeutic application. According to our results, secondary
structure and polarizability play the major role in determining the
drug-NRsinteractions.Theconservativemotifofthe NRistypically
described as three stacked alpha-helical sheets. The helices that
make up the ‘‘front’’ and ‘‘back’’ sheets are aligned parallel to one
another. The helices in the middle sheet run across the two outer
sheets and only occupy the space in the upper portion of the
domain. The space in the lower part of the domain is relatively void
of protein, and for most NRs, this creates an internal cavity for
small-molecule ligands [110]. Hydrogen bonds with polarizability
activity play a crucial role in protein-drug interactions (see, e.g.,
[11]).Ourapproachesand the resultsthusobtainedcouldbeusedto
demonstrate how nuclear hormone receptors form a network of
direct interactions. And this network increases in complexity to
describe the interactions with target genes as well as small molecules
known to bind a receptor, enzyme, or transporter.
A comprehensive drug-target interaction network system has
been established that contains four classifiers for predicting the
drugable interaction of compounds with enzymes, ion-channels,
GPCRs, and nuclear receptors, respectively. It is anticipated that
the network predictor system may become a very useful tool for
drug development. Particularly it may help us find new or
potential drug-target interactions.
Supporting Information
Online Supporting Information S1 The benchmark dataset for
the drug-target enzyme interaction system. It contains 8,157 gene-
drug pair samples, of which 2,719 are positive and 5,438 negative.
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